DGIdb - GANETESPIB Drug Record

GANETESPIB chembl:CHEMBL2103879 Antineoplastic

Alternate Names:

STA 9090
STA-9090
GANETESPIB

Drug Info:

Pharmaceutical Developer	Synta Pharmaceuticals
Source Reported Drug Name(s)	STA-9090(Ganetespib)
Drug Class	Chaperone Inhibitor
Drug Class	Small molecule inhibitor
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent

(5 More Sources)

Publications:

Smith et al., 2015, The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer., Target Oncol
Alexandrova et al., 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment., Nature
Landmann et al., 2014, UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib., Cell Death Dis
Shen et al., 2015, c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers., Cancer Res.
Acquaviva et al., 2014, Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib., Mol. Cancer Ther.

GANETESPIB UGT1A

Interaction Score: 3.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25210794

Sources:
CIViC
GANETESPIB HSP90AA2P

Interaction Score: 1.72

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
GANETESPIB HSP90AB1

Interaction Score: 0.56

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name STA-9090

Novel drug target Novel Target

Mechanism of Interaction Heat shock protein HSP90 inhibitor

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions
GANETESPIB BRAF

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type skin melanoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
25077897 24398428

Sources:
JAX-CKB
GANETESPIB HSP90AA1

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Heat shock protein HSP90 inhibitor

Direct Interaction yes

Trial Name STA-9090

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions CancerCommons
GANETESPIB MET

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type predicted – sensitive

Approval Status Preclinical - Cell culture

PMIDs:
26483207

Sources:
JAX-CKB
GANETESPIB ALK

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial
GANETESPIB EGFR

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Afatinib + Ganetespib

combination therapy Erlotinib + Ganetespib

Indication/Tumor Type non-small cell lung carcinoma

PMIDs:
25077897

Sources:
JAX-CKB
GANETESPIB TP53

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type resistant

Approval Status Preclinical

PMIDs:
26009011

Sources:
JAX-CKB

MyCancerGenome: GANETESPIB
- Version: 20-Jun-2017
Alternate Names:

STA-9090 Development Name

GANETESPIB Generic Name

Drug Info:

Drug Class Small molecule inhibitor

Publications:
CancerCommons: STA-9090
- Version: 25-July-2013
Alternate Names:

STA-9090 PubChem Drug Name

23624255 PubChem Drug ID

Ganetespib Drug Trade Name

Drug Info:

Drug Class Chaperone Inhibitor

Source Reported Drug Name(s) STA-9090(Ganetespib)

Pharmaceutical Developer Synta Pharmaceuticals

Publications:
TdgClinicalTrial: GANETESPIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

JAX-CKB: Ganetespib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Smith et al., 2015, The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer., Target Oncol

Shen et al., 2015, c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers., Cancer Res.

Acquaviva et al., 2014, Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib., Mol. Cancer Ther.

CIViC: GANETESPIB
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Landmann et al., 2014, UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib., Cell Death Dis
TALC: GANETESPIB
- Version: 12-May-2016
Alternate Names:

GANETESPIB Primary Drug Name

GANETESPIB Drug Generic Name

STA-9090 Drug Synonym

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL2103879
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: GANETESPIB
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL2103879
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	STA-9090
Novel drug target	Novel Target
Mechanism of Interaction	Heat shock protein HSP90 inhibitor

Indication/Tumor Type	skin melanoma
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

Mechanism of Interaction	Heat shock protein HSP90 inhibitor
Direct Interaction	yes
Trial Name	STA-9090

Indication/Tumor Type	non-small cell lung carcinoma
Response Type	predicted – sensitive
Approval Status	Preclinical - Cell culture

combination therapy	Afatinib + Ganetespib
combination therapy	Erlotinib + Ganetespib
Indication/Tumor Type	non-small cell lung carcinoma

Indication/Tumor Type	prostate cancer
Response Type	resistant
Approval Status	Preclinical

STA-9090	PubChem Drug Name
23624255	PubChem Drug ID
Ganetespib	Drug Trade Name

GANETESPIB	Primary Drug Name
GANETESPIB	Drug Generic Name
STA-9090	Drug Synonym

GANETESPIB Drug Record

GANETESPIB chembl:CHEMBL2103879 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25210794

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name STA-9090 Novel drug target Novel Target Mechanism of Interaction Heat shock protein HSP90 inhibitor

PMIDs: None found

Sources: MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type skin melanoma Response Type sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 25077897 24398428

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Heat shock protein HSP90 inhibitor Direct Interaction yes Trial Name STA-9090

PMIDs: None found

Sources: MyCancerGenome TdgClinicalTrial ChemblInteractions CancerCommons

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type non-small cell lung carcinoma Response Type predicted – sensitive Approval Status Preclinical - Cell culture

PMIDs: 26483207

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Afatinib + Ganetespib combination therapy Erlotinib + Ganetespib Indication/Tumor Type non-small cell lung carcinoma

PMIDs: 25077897

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type prostate cancer Response Type resistant Approval Status Preclinical

PMIDs: 26009011

Sources: JAX-CKB

MyCancerGenome: GANETESPIB

Alternate Names: STA-9090 Development Name GANETESPIB Generic Name

Drug Info: Drug Class Small molecule inhibitor

Publications:

CancerCommons: STA-9090

Alternate Names: STA-9090 PubChem Drug Name 23624255 PubChem Drug ID Ganetespib Drug Trade Name

Drug Info: Drug Class Chaperone Inhibitor Source Reported Drug Name(s) STA-9090(Ganetespib) Pharmaceutical Developer Synta Pharmaceuticals

Publications:

TdgClinicalTrial: GANETESPIB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

JAX-CKB: Ganetespib

Alternate Names:

Drug Info:

CIViC: GANETESPIB

Alternate Names:

Drug Info:

Publications: Landmann et al., 2014, UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib., Cell Death Dis

TALC: GANETESPIB

Alternate Names: GANETESPIB Primary Drug Name GANETESPIB Drug Generic Name STA-9090 Drug Synonym

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL2103879

Alternate Names:

Drug Info:

Publications:

MyCancerGenomeClinicalTrial: GANETESPIB

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL2103879

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
25210794

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name STA-9090

Novel drug target Novel Target

Mechanism of Interaction Heat shock protein HSP90 inhibitor

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type skin melanoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
25077897 24398428

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Heat shock protein HSP90 inhibitor

Direct Interaction yes

Trial Name STA-9090

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions CancerCommons

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type predicted – sensitive

Approval Status Preclinical - Cell culture

PMIDs:
26483207

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Afatinib + Ganetespib

combination therapy Erlotinib + Ganetespib

Indication/Tumor Type non-small cell lung carcinoma

PMIDs:
25077897

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type resistant

Approval Status Preclinical

PMIDs:
26009011

Sources:
JAX-CKB

Alternate Names:

STA-9090 Development Name

GANETESPIB Generic Name

Drug Info:

Drug Class Small molecule inhibitor

Alternate Names:

STA-9090 PubChem Drug Name

23624255 PubChem Drug ID

Ganetespib Drug Trade Name

Drug Info:

Drug Class Chaperone Inhibitor

Source Reported Drug Name(s) STA-9090(Ganetespib)

Pharmaceutical Developer Synta Pharmaceuticals

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

Landmann et al., 2014, UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib., Cell Death Dis

Alternate Names:

GANETESPIB Primary Drug Name

GANETESPIB Drug Generic Name

STA-9090 Drug Synonym